Altamira Therapeutics Announce – GuruFocus.com
HAMILTON, BERMUDA / ACCESSWIRE / December 16, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that the first group of patients has been randomized in a clinical trial with Bentrio™ (AM-301) in house dust mite (“HDM”) allergic rhinitis. Bentrio™, a drug-free nasal spray intended for personal protection against airborne viruses …….
HAMILTON, BERMUDA / ACCESSWIRE / December 16, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that the first group of patients has been randomized in a clinical trial with Bentrio™ (AM-301) in house dust mite (“HDM”) allergic rhinitis. Bentrio™, a drug-free nasal spray intended for personal protection against airborne viruses and allergens, is marketed in several countries already.
The trial will enroll a total of 36 patients with a history of perennial allergic rhinitis (PAR). It is designed to evaluate the efficacy of Bentrio™ in the treatment of PAR in an environmental exposure chamber (EEC), i.e. under controlled HDM exposure. Study participants will be randomized under an open label, three-period crossover design to receive either Bentrio™ in a single or double dose or no treatment prior to HDM exposure for three hours. The primary endpoint will be the change in the Total Nasal Symptom Score (TNSS) from baseline. The trial is being conducted at a single study site in Canada.
“Following the positive outcomes from our previous controlled pollen exposure study in seasonal allergic rhinitis, we expect this new study to demonstrate Bentrio’s protective effects also in perennial allergic rhinitis,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman and CEO. “Allergic rhinitis in both its seasonal and perennial form is a very common problem worldwide. We believe that Bentrio can help to provide important relief for many allergy sufferers based on its triple mode of action, free of any drug or preservative ingredients.”
Top-line results from the HDM trial are expected to become available in springtime.
About House Dust Mite Allergies
HDM allergens constitute the prime cause of respiratory allergies (i.e. allergic rhinitis and allergic asthma), with prevalence estimates for allergen sensitization ranging between 65 and 130 million persons in the general population worldwide, or as many as 50% among asthmatic patients.1 In the US population aged 6 years and older, dust mite allergens are the second most common source of sensitization right after plant-related allergens (20.3 and 27.1%, respectively).2 Unlike plant-related allergens, which tend to be seasonal (e.g. pollen / hay fever), HDMs may be present all year long. Symptoms of HDM allergies include sneezing, a runny or stuffy nose, itching, coughing, difficulty breathing, chest tightness or pain.
References
1 Calderon et al. (2015), Respiratory allergy caused by house dust mites: What do we really know?, J Allergy Clin Immunol 136(1):38-48.
2 Salo et al. (2014), Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005-2006. J Allergy Clin Immunol 134(2):350-9.
About Bentrio™
Bentrio™ (AM-301) is a drug-free nasal spray …….
